Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455013 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT00455013 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 93 participants.
The verdict
NCT00455013, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if belatacept (BMS-224818) is expected to show acceptable rates of acute rejection (AR) in steroid-free belatacept-based immunosuppressive regiments compared to a similar steroid-free tacrolimus regimen. The long-term safety and tolerability of belatacept based regimens following long-term administration in subjects who have received a kidney transplant
Interventions
- DRUG Sirolimus
- DRUG Thymoglobulin
- DRUG Tacrolimus
- DRUG Belatacept
- DRUG Mycophenolate Mofetil (MMF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2007-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00455013
The ClinicalTrials.gov registry entry for NCT00455013 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sirolimus is the first listed.
NCT00455013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00455013 about?
NCT00455013 is a clinical study titled "A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation". The purpose of this clinical research study is to learn if belatacept (BMS-224818) is expected to show acceptable rates of acute rejection (AR) in steroid-free belatacept-based immunosuppressive regiments compared to a similar steroid-free tacrolimus regimen. The long-term safety and tolerability of...
What is the current status of trial NCT00455013?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2007-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00455013?
The interventions under investigation include: Sirolimus (DRUG), Thymoglobulin (DRUG), Tacrolimus (DRUG), Belatacept (DRUG), Mycophenolate Mofetil (MMF) (DRUG).
Who is sponsoring clinical trial NCT00455013?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.